Specialty Pharmacy

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Emicizumab-kxwh (Hemlibra) is now the only FDA-approved treatment for hemophilia A with and without factor VIII inhibitors.

A combination of 2 anti-HIV antibodies may be capable of suppressing HIV for months after treatment.

Artificial intelligence tool can analyze images of patients’ lung tumors, specify cancer types, and identify altered genes driving abnormal cell growth.

Top news of the day from across the health care landscape.

The increased risk of cancer is due in part to people living with HIV living longer, thanks to advances like antiretroviral therapy.

FDA officials have approved omadacycline (Nuzyra, Paratek), a modernized tetracycline, to treat adults with acute skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

Study examines the role of liver macrophages as a long-lived HIV-1 cellular reservoir.

At the 2018 National Association of Specialty Pharmacy (NASP) Annual Meeting and Educational Conference, Mike Agostino, RPh, President of NASP, discussed how the organization advocates for the profession.

Top news of the day from across the health care landscape.

A new review of clinical trial data show the combination therapy elbasvir/grazoprevir (EBR/GR) has high rates of efficacy for patients with genotypes 1a, 1b, and 4 chronic hepatitis C (HCV) infection.

Epidiolex was approved to treat seizures associated with 2 rare and severe forms of epilepsy—Dravet syndrome and Lennox-Gastaut syndrome—in patients aged 2 years and older.

Based on evidence from a systematic review, researchers are calling for increased access to lifesaving hepatitis C treatments for injection drug users.

Top news of the day from across the health care landscape.

Brain inflammation caused by critical illness and infection may lead to the observed reduction in brain volume.

Latest approval for carfilzomib offers a more convenient dosing option for patients with multiple myeloma.

A high-touch patient care model with enhanced data collection may help stop the ongoing opioid problem.

Top news of the day from across the health care landscape.

According to FDA Commissioner Scott Gottlieb, MD, the agency’s approval of amikacin liposome inhalation suspension marks an important policy milestone.

Lymphatic vessels surrounding the brain may play a key role in the development and progression of multiple sclerosis.

Luis Torres, MBA, Vice President, Managed Care, BioPlus Specialty Pharmacy, discusses how collaboration between health care stakeholders is necessary to further the push towards a system that revolves around the patient.

Cemiplimab-rwlc (Libtayo) is the first and only treatment specifically approved and available for advanced cutaneous squamous cell carcinoma in the United States.

The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

Dacomitinib (Vizimpro, Pfizer) is indicated for patients with non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

Galcanezumab-gnlm (Emgality), a once monthly, self-administered 120-mg subcutaneous injection, is indicated for the preventive treatment of migraine in adults.

Top news of the week from Specialty Pharmacy Times.

Entrectinib showed a durable response and reduced tumors in patients with ROS1-positive non-small cell lung cancer.

Top news of the day from across the health care landscape.

A look at last week's top stories in the world of pharmacy.